Alaunos Therapeutics, Inc. Stock Issued During Period, Value, Stock Options Exercised
New shares the company issued (share-based compensation, option exercises, employee stock purchase plans, new issues, acquisitions), as filed in its 10-Q and 10-K XBRL statement of shareholders' equity. This is the dilution side; Issuer Repurchases is the other side.
- Alaunos Therapeutics, Inc. stock issued during period, value, stock options exercised for the quarter ending 2022-12-31 was $0.00.
- Alaunos Therapeutics, Inc. stock issued during period, value, stock options exercised for the quarter ending 2022-09-30 was $21.00K, a 2000.00% increase year-over-year.
- Alaunos Therapeutics, Inc. stock issued during period, value, stock options exercised for the quarter ending 2021-12-31 was -$1.00K, a 100.25% decline year-over-year.
- Alaunos Therapeutics, Inc. stock issued during period, value, stock options exercised for the quarter ending 2021-09-30 was $1.00K, a 96.30% decline year-over-year.
- Alaunos Therapeutics, Inc. stock issued during period, value, stock options exercised for fiscal 2022 was $21.00K, a 97.97% decline from fiscal 2021.
- Alaunos Therapeutics, Inc. stock issued during period, value, stock options exercised for fiscal 2021 was $1.04M, a 134.39% increase from fiscal 2020.
- Alaunos Therapeutics, Inc. stock issued during period, value, stock options exercised for fiscal 2020 was $442.00K, a 63.74% decline from fiscal 2019.
- Alaunos Therapeutics, Inc. stock issued during period, value, stock options exercised for fiscal 2019 was $1.22M, a 403.72% increase from fiscal 2018.
| Period end | Stock Issued During Period, Value, Stock Options Exercised 3 month | Stock Issued During Period, Value, Stock Options Exercised 12 month |
|---|---|---|
| 2022-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2024-04-01 | $21.00K 10-K · filed 2024-04-01 |
| 2022-09-30 | $21.00K 10-Q · filed 2023-11-14 | |
| 2021-12-31 | -$1.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-07 | $1.04M 10-K · filed 2023-03-07 |
| 2021-09-30 | $1.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-14 | $1.44M derived: sum of 4 quarters · filed 2022-11-14 |
| 2021-06-30 | $20.00K 10-Q · filed 2022-08-15 | $1.46M derived: sum of 4 quarters · filed 2022-08-15 |
| 2021-03-31 | $1.02M 10-Q · filed 2022-05-16 | $1.45M derived: sum of 4 quarters · filed 2022-05-16 |
| 2020-12-31 | $399.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-30 | $442.00K 10-K · filed 2022-03-30 |
| 2020-09-30 | $27.00K 10-Q · filed 2021-11-08 | $242.00K derived: sum of 4 quarters · filed 2021-11-08 |
| 2020-06-30 | $12.00K 10-Q · filed 2021-08-13 | $635.00K derived: sum of 4 quarters · filed 2021-08-13 |
| 2020-03-31 | $4.00K 10-Q · filed 2021-05-06 | $1.22M derived: sum of 4 quarters · filed 2021-05-06 |
| 2019-12-31 | $199.00K derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-01 | $1.22M 10-K · filed 2021-03-01 |
| 2019-09-30 | $420.00K 10-Q · filed 2020-11-05 | |
| 2019-06-30 | $600.00K 10-Q · filed 2020-08-06 | |
| 2018-12-31 | $2.00K derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-01 | $242.00K 10-K · filed 2021-03-01 |
| 2018-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-07 | |
| 2018-06-30 | $240.00K 10-Q · filed 2019-08-08 | |
| 2017-12-31 | -$11.00K derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-02 | $88.00K 10-K · filed 2020-03-02 |
| 2017-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-06 | $262.00K derived: sum of 4 quarters · filed 2019-03-05 |
| 2017-06-30 | $70.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2017-07-31 | $262.00K derived: sum of 4 quarters · filed 2019-03-05 |
| 2017-03-31 | $29.00K 10-Q · filed 2017-05-01 | |
| 2016-12-31 | $163.00K derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-05 | $714.00K 10-K · filed 2019-03-05 |
| 2016-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2016-11-09 | |
| 2015-12-31 | $1.20M derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-01 | $4.57M 10-K · filed 2018-03-01 |
| 2015-09-30 | $226.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2015-11-02 | $3.43M derived: sum of 4 quarters · filed 2017-02-16 |
| 2015-06-30 | $599.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2015-08-10 | $3.21M derived: sum of 4 quarters · filed 2017-02-16 |
| 2015-03-31 | $2.54M 10-Q · filed 2015-05-07 | $2.96M derived: sum of 4 quarters · filed 2017-02-16 |
| 2014-12-31 | $63.00K derived: 10-K 12 month − 10-Q 9 month · filed 2017-02-16 | $1.39M 10-K · filed 2017-02-16 |
| 2014-09-30 | $6.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2014-10-30 | $1.32M derived: sum of 4 quarters · filed 2014-10-30 |
| 2014-06-30 | $348.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2014-08-07 | $1.42M derived: sum of 4 quarters · filed 2014-08-07 |
| 2014-03-31 | $969.00K 10-Q · filed 2014-05-08 | $1.07M derived: sum of 4 quarters · filed 2014-05-08 |
| 2013-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2014-03-03 | $956.00K 10-K · filed 2014-03-03 |
| 2013-09-30 | $102.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2013-10-22 | |
| 2013-06-30 | $3.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2013-08-08 | |
| 2013-03-31 | $851.00K 10-Q · filed 2013-05-07 | |
| 2012-09-30 | $0.00 derived: 10-Q 9 month − 10-Q/A 6 month · filed 2012-11-08 | |
| 2011-09-30 | $55.00K derived: 10-Q 9 month − 10-Q/A 6 month · filed 2011-11-03 | |
| 2007-12-31 | $36.00K 10-K · filed 2014-03-03 | |
| 2006-12-31 | $25.00K 10-K · filed 2014-03-03 | |
| 2005-12-31 | $4.00K 10-K · filed 2014-03-03 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Genprex, Inc. (GNPX) | United States | $0.003B | -0.02 |
| Silo Pharma, Inc. (SILO) | United States | $0.003B | -1.57 |
| GeoVax Labs, Inc. (GOVX) | United States | $0.003B | -0.45 |
| Petros Pharmaceuticals, Inc. (PTPI) | United States | $0.003B | |
| Sunshine Biopharma Inc. (SBFM) | $0.003B | ||
| Matinas BioPharma Holdings, Inc. (MTNB) | United States | $0.003B | |
| ZyVersa Therapeutics, Inc. (ZVSA) | United States | $0.002B | |
| Aptevo Therapeutics Inc. (APVO) | United States | $0.003B | |
| BioXcel Therapeutics, Inc. (BTAI) | United States | $0.002B | |
| JUPITER NEUROSCIENCES, INC. (JUNS) | United States | $0.002B | -0.02 |